WO2002030443A3 - Regulation of human skin healing - Google Patents

Regulation of human skin healing Download PDF

Info

Publication number
WO2002030443A3
WO2002030443A3 PCT/US2001/031555 US0131555W WO0230443A3 WO 2002030443 A3 WO2002030443 A3 WO 2002030443A3 US 0131555 W US0131555 W US 0131555W WO 0230443 A3 WO0230443 A3 WO 0230443A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
human skin
skin healing
vascularized
reconstructs
Prior art date
Application number
PCT/US2001/031555
Other languages
French (fr)
Other versions
WO2002030443A9 (en
WO2002030443A2 (en
Inventor
Meenhard Herlyn
Carola Berking
Kapaettu Satyamoorthy
Omaida Velazquez
Original Assignee
Wistar Inst
Meenhard Herlyn
Carola Berking
Kapaettu Satyamoorthy
Omaida Velazquez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Meenhard Herlyn, Carola Berking, Kapaettu Satyamoorthy, Omaida Velazquez filed Critical Wistar Inst
Priority to US10/398,980 priority Critical patent/US20040031067A1/en
Priority to AU2002211561A priority patent/AU2002211561A1/en
Publication of WO2002030443A2 publication Critical patent/WO2002030443A2/en
Publication of WO2002030443A3 publication Critical patent/WO2002030443A3/en
Publication of WO2002030443A9 publication Critical patent/WO2002030443A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

The invention relates to new compositions and methods for preparing vascularized dermal reconstructs, vascularized skin grafts, and for enhancing vascularization in situ in response to a variety of medical conditions.
PCT/US2001/031555 2000-10-11 2001-10-11 Regulation of human skin healing WO2002030443A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/398,980 US20040031067A1 (en) 2001-10-11 2001-10-11 Regulation of human skin healing
AU2002211561A AU2002211561A1 (en) 2000-10-11 2001-10-11 Regulation of human skin healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23912300P 2000-10-11 2000-10-11
US60/239,123 2000-10-11

Publications (3)

Publication Number Publication Date
WO2002030443A2 WO2002030443A2 (en) 2002-04-18
WO2002030443A3 true WO2002030443A3 (en) 2003-05-30
WO2002030443A9 WO2002030443A9 (en) 2003-11-13

Family

ID=22900707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031555 WO2002030443A2 (en) 2000-10-11 2001-10-11 Regulation of human skin healing

Country Status (2)

Country Link
AU (1) AU2002211561A1 (en)
WO (1) WO2002030443A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623638B (en) * 2015-01-20 2018-06-19 奥思达干细胞有限公司 A kind of stem cell patch of melanoma and preparation method thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
ES2263382B1 (en) 2005-05-16 2007-11-16 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon ARTIFICIAL MATRIX OF ENDOTHELIZED FIBRINE GEL SUPERPRODUCTOR OF PROANGIOGEN FACTORS.
EP1948246B1 (en) * 2005-11-14 2017-05-03 Theragene Pharmaceuticals, Inc. Stem cell factor therapy for tissue injury
CN107349474A (en) * 2017-06-18 2017-11-17 广东博溪生物科技有限公司 A kind of artificial dermis construction method of anti-shrinkage
CN112826920A (en) * 2021-01-23 2021-05-25 中国人民解放军陆军军医大学 Application of ID1/ID3 in inducing reprogramming of fibroblasts into Schwann cells to promote nerve regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
WO2000006195A1 (en) * 1998-07-31 2000-02-10 University Of Southern California Targeting pharmaceutical agents to injured tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
WO2000006195A1 (en) * 1998-07-31 2000-02-10 University Of Southern California Targeting pharmaceutical agents to injured tissues

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF OPHTHALMOLOGY, vol. 113, no. 4, 1995, pages 512 - 520, ISSN: 0003-9950 *
BRITISH JOURNAL OF PLASTIC SURGERY, vol. 47, 1994, pages 349 - 359 *
CANCER RESEARCH, vol. 54, no. 21, 1994, pages 5689 - 5694, ISSN: 0008-5472 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988, THOMPSON J A ET AL: "SITE-DIRECTED NEOVESSEL FORMATION IN-VIVO", XP002202809, Database accession no. PREV198886111080 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, HANSSON H-A ET AL: "TRANSIENT EXPRESSION OF INSULIN-LIKE GROWTH FACTOR I IMMUNOREACTIVITY BY VASCULAR CELLS DURING ANGIOGENESIS", XP002202810, Database accession no. PREV198988012666 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, COOPER M L ET AL: "USE OF A COMPOSITE SKIN GRAFT COMPOSED OF CULTURED HUMAN KERATINOCYTES AND FIBROBLASTS AND A COLLAGEN GAG MATRIX TO COVER FULL-THICKNESS WOUNDS ON ATHYMIC MICE", XP002202805, Database accession no. PREV199191085558 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, SERS CHRISTINE ET AL: "MUC18, A melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread.", XP002202802, Database accession no. PREV199598008320 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, SAKAMOTO TAIJI ET AL: "Vessel Formation by Choroidal Endothelial Cells In Vitro Is Modulated by Retinal Pigment Epithelial Cells.", XP002202808, Database accession no. PREV199598274220 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, BONIFATI C ET AL: "Serum endothelin-1 levels are increased in psoriatic patients and correlate with disease severity.", XP002202806, Database accession no. PREV199799566570 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2000 (2000-04-01), PELLETIER LAURENT ET AL: "An in vitro model for the study of human bone marrow angiogenesis: Role of hematopoietic cytokines.", XP002202804, Database accession no. PREV200000264047 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 1999 (1999-05-01), SWIERCZ RAFAL ET AL: "Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.", XP002202803, Database accession no. PREV199900258480 *
DATABASE MEDLINE [online] CARMELIET ET AL: "MOLECULAR ANALYSIS OF BLOOD VESSEL FORMATION AND DISEASE", XP002202801, Database accession no. NLM9374741 *
DATABASE MEDLINE [online] LEES ET AL: "A FREEZE-INJURED SKIN GRAFT MODEL FOR THE QUANTITATIVE STUDY OF BASIC FIBROBLAST GROWTH FACTOR AND OTHER PROMOTERS OF ANGIOGENESIS IN WOUND HEALING", XP002202807, Database accession no. NLM7522103 *
EMING SABINE A ET AL: "Enhanced function of cultured epithelium by genetic modification: Cell-based synthesis and delivery of growth factors.", BIOTECHNOLOGY AND BIOENGINEERING, vol. 52, no. 1, 1996, pages 15 - 23, XP002202800, ISSN: 0006-3592 *
EXPERIMENTAL AND MOLECULAR PATHOLOGY, vol. 50, no. 1, 1989, pages 125 - 138, ISSN: 0014-4800 *
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 10, no. 1, 1997, pages 81 - 82, ISSN: 0394-6320 *
LABORATORY INVESTIGATION, vol. 80, no. 4, April 2000 (2000-04-01), pages 501 - 511, ISSN: 0023-6837 *
ONCOLOGY REPORTS, vol. 6, no. 3, May 1999 (1999-05-01), pages 523 - 526, ISSN: 1021-335X *
SCIENCE (WASHINGTON D C), vol. 241, no. 4871, 1988, pages 1349 - 1352, ISSN: 0036-8075 *
SURGERY (ST LOUIS), vol. 109, no. 2, 1991, pages 198 - 207, ISSN: 0039-6060 *
THE AMERICAN JOURNAL OF PHYSIOLOGY, vol. 273, no. 5PT2, 1997, pages H2091 - H2104 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623638B (en) * 2015-01-20 2018-06-19 奥思达干细胞有限公司 A kind of stem cell patch of melanoma and preparation method thereof

Also Published As

Publication number Publication date
WO2002030443A9 (en) 2003-11-13
AU2002211561A1 (en) 2002-04-22
WO2002030443A2 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU4680800A (en) Biomimetic water solutions and compositions, their use as and in health and beauty care products and the methods to prepare them
DK0879024T3 (en) Impression system for an implant termination that protrudes in relation to the human tissue structure
WO2001074314A3 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU2525401A (en) Use of an extract of at least one vaccinium-type plant as an anti-glycation agent
EG23321A (en) Artificial dermis and method of preparation.
WO2003028691A3 (en) Stable compositions containing ethanolamine derivatives and glucosides
WO2005065269A3 (en) Compositions and method for decreasing the appearance of skin wrinkles
WO2001092477A3 (en) Three-dimensional skin model
GB9919681D0 (en) Improvements relating to medical injectors and skin prickers
AU6769701A (en) Sprayable wound care compositions
AU2001240940A1 (en) Cosmetic and dermatological composition for psoriatic skin, scalp treatment and care
DK1204335T3 (en) Method of beautifying the shape of a human body using a cosmetic patch
WO2006018454A3 (en) Cosmetic preparation comprising hyaluronic acid and saponins for treatment of skin aging phenomena
WO2001032840A3 (en) Hair transplantation
WO2002064088A3 (en) Pharmaceutical composition for the treatment of alopecia
EP1172084A3 (en) Cosmetic and dermatologic composition to eliminate sebum
TW200518781A (en) Compositions for achieving benefits in skin using key cellular metabolic intermediates
AU2002347271A1 (en) Cosmetic composition for human skin and hair care
WO2002030443A3 (en) Regulation of human skin healing
AU4262599A (en) Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
WO2003037288A3 (en) Cosmetic composition that mimics sebum and the use thereof
WO2002096369A3 (en) Haircare agent comprising natural oils
WO2005009456A3 (en) Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2003032909A3 (en) Methods of treating skin with diphosphonate derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10398980

Country of ref document: US

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)